Function Health Real Customer Outcomes: An Independent Evidence Review

What Function Health Actually Offers

Function Health provides a subscription-based laboratory testing service that bundles over 100 biomarkers into a single annual or semi-annual panel. Members receive results through a proprietary dashboard that flags values outside optimal ranges, not just conventional reference ranges.

The panel covers metabolic markers (fasting glucose, HbA1c, fasting insulin, HOMA-IR), cardiovascular risk markers (ApoB, Lp(a), hsCRP, homocysteine, a full lipid panel), hormones (total and free testosterone, estradiol, DHEA-S, thyroid panel including free T3 and reverse T3), organ function tests (comprehensive metabolic panel, GGT, ferritin), and cancer screening markers (PSA for men, CA-125 as an optional add-on). Lab draws happen at Quest Diagnostics patient service centers. A licensed physician reviews every result set before release, satisfying state-level laboratory ordering requirements.

The company positions itself within the "longevity medicine" space, a category that has grown rapidly since Peter Attia's 2023 book Outlive popularized the concept of proactive biomarker tracking. Function Health's co-founder Dr. Mark Hyman has stated publicly that "the current healthcare system waits for disease; we measure to prevent it." That framing resonates with a growing consumer base. But does the data support the model?

The Evidence Behind Broad Biomarker Screening

No randomized controlled trial has evaluated Function Health's specific panel as a bundled intervention. That gap matters. The service's clinical value rests on the evidence behind each individual marker and whether acting on results actually changes outcomes.

For some markers, the evidence is strong. The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 who have overweight or obesity, based on consistent evidence that early detection plus lifestyle intervention reduces progression to diabetes by 58% over three years, as demonstrated in the Diabetes Prevention Program (DPP) trial (N=3,234) [1][2]. HbA1c, fasting glucose, and fasting insulin, all included in the Function Health panel, are the standard screening tools.

Cardiovascular risk markers present a similarly strong case. A 2021 meta-analysis in JAMA Cardiology (N=398,718 across 21 studies) found that elevated ApoB predicted major adverse cardiovascular events more accurately than LDL-C, reclassifying risk in approximately 25% of patients who would have been missed by LDL-C alone [3]. The European Atherosclerosis Society and the Canadian Cardiovascular Society both recommend ApoB measurement in risk assessment [4]. Lp(a), another marker on the Function Health panel, is an independent genetic risk factor present in roughly 20% of the global population, and the 2024 European Society of Cardiology guidelines recommend measuring it at least once in every adult's lifetime [5].

Other markers carry weaker screening evidence. Reverse T3, included in the Function Health thyroid panel, lacks guideline support from either the American Thyroid Association or the Endocrine Society as a useful clinical marker in euthyroid patients [6]. Homocysteine screening in the general population is not recommended by the USPSTF due to insufficient evidence that treatment of elevated homocysteine reduces cardiovascular events [7].

Do Customers Actually Change Behavior?

The critical question for any screening service is whether test results lead to meaningful action. Function Health publishes testimonials on its website describing members who discovered elevated HbA1c, high ApoB, or low vitamin D and subsequently made dietary changes or sought treatment. These anecdotes are not outcome data.

The best proxy evidence comes from studies of health screening programs in general. A 2019 Cochrane systematic review of 17 RCTs (N=251,891) evaluating general health checks found no reduction in total mortality or cardiovascular mortality from screening alone [8]. The review authors noted that "screening identifies risk factors but does not guarantee that patients will receive or adhere to effective interventions."

That finding does not necessarily invalidate Function Health's model. The Cochrane review largely evaluated traditional primary care health checks with passive follow-up. Function Health's dashboard, flagging system, and emphasis on repeated testing every six months could theoretically improve engagement. Dr. Robert Lustig, professor emeritus of pediatrics at UCSF, has argued that "the difference between a lab result on paper and a lab result on a dashboard you check monthly is the difference between information and motivation" [9]. Whether that motivational gap translates into measurable outcome differences remains unproven.

One area where repeated testing shows clear value is lipid management. The 2018 AHA/ACC cholesterol guidelines recommend serial lipid monitoring to confirm response to statin therapy, with a target of 30% or greater LDL-C reduction in moderate-intensity regimens [10]. A member who discovers elevated ApoB through Function Health, starts a statin through their own physician, and retests at six months is following a well-supported clinical pathway. The question is whether the $499 annual fee represents efficient access to that pathway compared to ordering the same labs through a primary care visit.

Function Health vs. Alternatives

Several competitors occupy the direct-to-consumer lab testing space. Understanding how Function Health compares requires examining panel breadth, cost, clinical integration, and follow-up support.

InsideTracker offers tiered plans ranging from roughly $249 to $589 per blood draw, with 5 to 43 biomarkers depending on the tier. Its "Ultimate" plan includes fewer markers than Function Health's standard panel but adds algorithm-driven dietary and supplement recommendations. InsideTracker has published peer-reviewed research using its platform data, including a 2023 study in Nutrients (N=1,032) showing that users who followed its recommendations improved their "InnerAge" biological age score by an average of 2.6 years over 12 months [11]. That study had no control group and used a proprietary composite endpoint, but it represents more published evidence than Function Health currently offers.

Marek Health targets the hormone optimization and bodybuilding community, offering comprehensive hormone and metabolic panels starting around $250. Marek provides direct telemedicine physician consultations and can prescribe hormone therapy, a capability Function Health does not offer. For individuals specifically seeking testosterone replacement therapy or hormonal optimization, Marek's model provides a more integrated clinical pathway.

Traditional primary care remains the baseline comparator. A standard annual physical with bloodwork ordered through insurance typically covers a basic metabolic panel, CBC, lipid panel, and TSH. Cost to the patient varies but is often zero under preventive care mandates of the Affordable Care Act [12]. The trade-off is a narrower panel. Most primary care physicians do not routinely order ApoB, Lp(a), fasting insulin, DHEA-S, or free testosterone unless clinical suspicion warrants it.

A 2022 analysis published in JAMA Internal Medicine estimated that adding ApoB, Lp(a), and hsCRP to standard screening in adults aged 40 to 75 would cost approximately $14.50 per patient in additional lab fees and could reclassify cardiovascular risk in up to 23% of those screened [13]. That per-test cost is far below Function Health's annual fee, though it does not account for the friction of convincing a physician to order non-standard tests.

Cost-Effectiveness: Where the Math Gets Complicated

Function Health's $499 annual membership buys two comprehensive panels per year. At retail Quest Diagnostics pricing, ordering 100-plus biomarkers individually without insurance would cost between $2,000 and $4,000. By that math, the service offers significant savings on raw lab cost. But that comparison assumes a person needs all 100-plus markers.

The USPSTF grades its screening recommendations using an evidence hierarchy. Only a fraction of Function Health's markers carry an "A" or "B" recommendation for population-level screening: lipid screening (grade B for adults 40-75), prediabetes screening (grade B for adults 35-70 with overweight/obesity), and hepatitis C screening (grade B, one-time for all adults) [14]. Many other markers, including sex hormones, micronutrients, and inflammatory markers in asymptomatic individuals, lack sufficient evidence for population-wide screening.

A person who selectively orders USPSTF-recommended screening through their primary care physician and insurance might spend $0 to $50 out of pocket annually. A person who wants the broader panel but negotiates specific add-ons with their physician (ApoB, fasting insulin, Lp(a), vitamin D, ferritin) might spend $100 to $200 in additional lab fees through services like LabCorp or Quest direct-access testing. Function Health's value proposition is strongest for the person who wants maximal biomarker coverage, prefers a curated dashboard over raw lab printouts, and is willing to pay a premium for convenience.

Legitimate Strengths of the Model

Dismissing Function Health entirely would ignore genuine gaps in conventional care. The average primary care visit in the United States lasts 18 minutes [15]. Physicians operating under time pressure and insurance constraints often default to minimum screening panels. Conditions like prediabetes remain underdiagnosed: the CDC estimates that of 98 million American adults with prediabetes, 80% are unaware of their status [16].

Function Health's model addresses this gap in two practical ways. First, it removes the friction of requesting non-standard labs from a busy physician. Second, serial testing every six months creates a longitudinal biomarker trajectory that most primary care practices do not provide. Trend data, a fasting insulin rising from 5 to 12 mIU/L over 18 months while still technically "normal," can signal metabolic deterioration years before an HbA1c crosses the diagnostic threshold of 6.5%.

Dr. Jason Fung, nephrologist and author of The Diabetes Code, has noted that "fasting insulin is perhaps the earliest marker of metabolic dysfunction, yet almost no physician orders it routinely" [17]. Function Health includes fasting insulin in its standard panel.

Legitimate Concerns

Three concerns warrant attention. First, over-testing in low-risk populations can generate false positives. A panel of 100-plus markers tested in a healthy 30-year-old will, by statistical probability alone, produce roughly five results outside the 95th-percentile reference range purely by chance. Function Health uses "optimal" ranges narrower than standard reference ranges, which could increase the false-positive rate further. Unnecessary follow-up testing, specialist referrals, and patient anxiety are documented harms of over-screening [18].

Second, Function Health does not prescribe. A member who discovers clinically actionable results (severely elevated ApoB, HbA1c of 6.8%, testosterone below 200 ng/dL) must still manage their own healthcare system to act on those findings. The service identifies problems but does not resolve them. For uninsured or underinsured members, this gap could leave actionable findings stranded.

Third, the "longevity" framing, while motivating, risks overpromising. No biomarker panel has been shown to extend lifespan in a randomized trial. Biomarker optimization is a plausible strategy supported by mechanistic and observational evidence, but calling it "longevity medicine" implies a certainty the data does not yet support.

Who Benefits Most

The strongest use case for Function Health is an engaged, health-literate adult aged 35 to 65 who has a primary care physician willing to act on outside lab results, wants deeper metabolic and cardiovascular risk stratification beyond standard panels, and can afford $499 annually without financial strain. The weakest use case is an anxious young adult with no risk factors who may generate unnecessary worry from false-positive results, or an uninsured person who cannot afford follow-up care for detected abnormalities.

Function Health fills a real niche between the 18-minute annual physical and a $5,000-plus executive health program at an academic medical center. Whether that niche justifies its cost depends entirely on what you do with the data. A 2020 study in The BMJ found that providing patients with personalized cardiovascular risk information increased statin initiation by 13% compared to usual care (NNT = 8) [19]. Information changes behavior, but only when paired with access to treatment.

The CDC recommends that adults with prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) enroll in a structured lifestyle change program, which has been shown to reduce diabetes risk by 58% and sustain a 34% risk reduction at 10 years in the DPP long-term follow-up [20].